Hepatic stellate cell

Gyre Therapeutics Presents Poster at the American Association for the Study of Liver Diseases (AASLD) Annual Liver Meeting

Retrieved on: 
Monday, November 13, 2023
Steatohepatitis, SAN, Therapy, Health, Cirrhosis, AASLD, TGF, Hepatic stellate cell, Chronic liver disease, MASH, Poster, Ocean gyre, Boston

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (NASDAQ: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver diseases, today announced the presentation of a poster at the American Association for the Study of Liver Diseases’ (AASLD) Annual Liver Meeting, November 10-14, 2023, in Boston, Massachusetts.

Key Points: 
  • SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (NASDAQ: GYRE), a clinical-stage biotechnology company developing anti-fibrotic therapeutics for a variety of chronic liver diseases, today announced the presentation of a poster at the American Association for the Study of Liver Diseases’ (AASLD) Annual Liver Meeting, November 10-14, 2023, in Boston, Massachusetts.
  • Gyre’s lead asset, Hydronidone, is currently being investigated for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH)-associated liver fibrosis in the United States.
  • Gyre’s poster presented the potential antifibrotic effects of Hydronidone and its expected mode of action in mouse hepatic fibrosis models.
  • The obtained mechanistic data support the potential of Hydronidone for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases.

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

NOSTER Research: Gut bacteria derived metabolites offer alternative treatment for fatty liver disease

Retrieved on: 
Monday, November 27, 2023
Research, Scar, Gene, Cirrhosis, Mouse, Liver, Liver disease, HYA, Non-alcoholic fatty liver disease, Patient, Pioglitazone, Obesity, Linoleic acid, TGF, Hepatic stellate cell, Bacteria, Death, Shizuoka University, Lactobacillus, Scientific Reports, Inflammation, Fibrosis, Dietary supplement, Vaccine, NAFLD

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.

Key Points: 
  • Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition that affects a sizable population of the developed world.
  • A deeper analysis revealed that pioglitazone in fact increased the Lactobacillus species of bacteria in the gut, which in turn were generating the metabolites.
  • Nonalcoholic fatty liver disease (NAFLD) and fibrosis: NAFLD is a chronic form of liver disease that affects 25% of the world's population—most likely people who do not consume much alcohol.
  • A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF–β signaling in hepatic stellate cells.

Laekna, a Biotechnology Company in China, Listed on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Thursday, June 29, 2023
IIA, Stock exchange, Bimagrumab, Prednisone, Sintilimab, Patient, Investment, Federal Medical Centres, Mab, Cornerstone, Prostate cancer, Biomedical Research, Clinical trial, Hepatic stellate cell, Research, Motherboard, Drug discovery, Knowledge, FDA, IND, Frost, Cirrhosis, Global Health Innovative Technology Fund, International, Biotechnology, Cancer, Breakthrough therapy, AKT, Core product, CYP17A1, CYP11B2, Social responsibility, Drug development, Liver disease, ATP, Drug resistance, Trust, Limited partnership, Multi, Hong Kong Stock Exchange, SCGC, HK, Management, Pharmaceutical industry, IPO, Novartis

HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").

Key Points: 
  • HONG KONG, June 29, 2023 - (ACN Newswire) - A biotechnology company in China - Laekna, Inc. (stock code: 2105.HK), today listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange").
  • (2) Use for advancing the clinical development and approval of the other Core Product of the Company, LAE002.
  • The Hong Kong Offering also recorded an over-subscription, of approximately 5.81 times of the 6,373,000 shares offered.
  • The Company has established a number of global and regional partnerships with leading pharmaceutical companies, including Novartis and Innovent.

ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis

Retrieved on: 
Monday, July 17, 2023
ASC, Hepatic stellate cell, NLRP3, Inflammation, Inflammasome, Health, Super Meat Boy, Patient, Mouse, Therapy, Cirrhosis, Clothing, Pharmaceutical industry, Medical imaging, Hepatology

In the paper titled, “Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis,” the authors evaluated serum levels of IL-18 in patients diagnosed with liver fibrosis/cirrhosis, and they conducted studies in three different mouse models of liver fibrosis.

Key Points: 
  • In the paper titled, “Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis,” the authors evaluated serum levels of IL-18 in patients diagnosed with liver fibrosis/cirrhosis, and they conducted studies in three different mouse models of liver fibrosis.
  • Following are key findings reported in the paper:
    The pivotal role of IL-18 signaling in liver fibrosis was confirmed in IL-18 deficient mice, which showed protection from fibrotic liver changes
    The authors stated, “Our results highlight the pivotal role of IL-18 signaling in liver fibrogenesis through the activation of HSCs in vitro and in vivo in three different mouse models.” To read the article, Click Here .
  • “The research published in the Hepatology demonstrated that NLRP3 inflammasome-mediated activation of IL-18 has a pivotal role in liver fibrosis, providing support for inflammasome inhibition as a promising treatment.
  • To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)

Retrieved on: 
Tuesday, June 6, 2023
Overload, Pancreatitis, University, RAP, Inflammation, Terminal, SOCE, University of Szeged, CRAC, Hepatic stellate cell, CP, Research, JCI, Fibrosis, Journal, HIV disease progression rates, Patient, Manuscript, SARAF, Journal of Clinical Investigation, Mouse, PSC, Insight, Pharmaceutical industry

LA JOLLA, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the publication of preclinical data in The Journal of Clinical Investigation (JCI) Insight that details the potential benefit of CRAC channel inhibitors for chronic pancreatitis (CP). The study, titled “Orai1 calcium channel inhibition prevents progression of chronic pancreatitis,” was conducted by József Maléth, M.D., Ph.D., and his team at University of Szeged and the manuscript was co-authored by CalciMedica’s co-founder and Chief Scientific Officer, Ken Stauderman, Ph.D., and CalciMedica’s Chief Medical Officer, Sudarshan Hebbar, M.D.

Key Points: 
  • “We are encouraged by the data gathered in this study, which illustrate the potential benefit of Orai1 inhibition with a selective CRAC channel inhibitor for the treatment of chronic pancreatitis,” said Dr. Stauderman.
  • In addition, a decrease in fibrosis was observed in the mouse model, consistent with a significant reduction in the severity of CP.
  • These results support the initiation of clinical studies to assess the beneficial effects of Orai1 inhibition in patients with RAP and early CP.
  • These compounds are moving through pre-IND studies and could be ready for clinical studies in late 2024.”

Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease

Retrieved on: 
Thursday, January 5, 2023
Liver cancer, Fibrosis, Cancer, Icahn School of Medicine at Mount Sinai, Fatty liver disease, Cirrhosis, Mouse, Protein, Weizmann Institute of Science, Lung, Research, Scar, Type 2 diabetes, Institute of Liver and Biliary Sciences, NTRK3, NASH, University of California, Glass, Division, NAFLD, Non-alcoholic fatty liver disease, Liver failure, Disease, Hepatic stellate cell, Tissue, Yale School of Medicine, Liver disease, Patient, Mount Sinai, Science Translational Medicine, Heart, University, Hypertension, University of Edinburgh, Hepatitis, P30, Doctor of Philosophy, Sammi, Cell, Liver, Therapeutic discovery project, Medical imaging, Pharmaceutical industry, Dietary supplement, MD, Medicine

NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD). The research was led by investigators at the Icahn School of Medicine at Mount Sinai.

Key Points: 
  • Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • Utilizing these innovative methods, the investigators discovered a network of cell-to-cell communication driving scarring as liver disease advances.
  • NEW YORK, Jan. 5, 2023 /PRNewswire-PRWeb/ -- Using the latest technologies—including both single-nuclear sequencing of mice and human liver tissue and advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for non-alcoholic fatty liver disease (NAFLD).
  • They identified a shared number of 68 pairs of potential drug targets across the two species.

Embryll Launches Innovative Service that Restores Pets Back to Their Youthful State

Retrieved on: 
Tuesday, May 3, 2022
PETS, Parent, Dog, B cell, Rejuvenation, Happiness, Astrocyte, Hepatic stellate cell, Neuron, Animal, Hepatocyte, DNA, History, Pet, Veterinarian, Efficiency, LOS, Ageing, Technology, Research, Cell, Toy, Vaccine, Medical imaging

LOS ANGELES, May 3, 2022 /PRNewswire/ -- Losing a beloved pet or watching them suffer through an ailment can be a heart-wrenching situation. Pets hold a special place in their human families' lives, and their pet parents often will go to great lengths to prolong their pets' lives and wellbeing. With this in mind, one innovative research and development startup, Embryll, is helping families with pets buy more time with their furry friends thanks to a cutting-edge cellular transplantation process that restores their pets to their youthful state.

Key Points: 
  • Pets hold a special place in their human families' lives, and their pet parents often will go to great lengths to prolong their pets' lives and wellbeing.
  • With this in mind, one innovative research and development startup, Embryll, is helping families with pets buy more time with their furry friends thanks to a cutting-edge cellular transplantationprocess that restores their pets to their youthful state.
  • California-based Embryll leverages oocyte-based reprogramming and animal cloning in creating its newly launch services aimed and extending the lives and youthful vitality of pets.
  • Veterinarians looking to become accredited in Embryll process can apply for consideration via Embryll's site.

STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Apoptosis, News, Nausea, Discovery, Daewoong Pharmaceutical, Jiangsu Hengrui Medicine, STAT3, III, STAT5, Protein, Hepatic stellate cell, STAT5B, Acquisition, II, Infection, Clinical trial, STAT1, JAK3, STAT6, STAT5A, JAK2, COVID, STAT inhibitors, Niclosamide, Therapy, Oxidative phosphorylation, JAK1, Tyrosine, Oligonucleotide, Signal, STAT, Vomiting, Fatigue, JAK, Peptidomimetic, Pharmaceutical industry

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.
  • This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.
  • The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e.
  • The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D.

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine

Retrieved on: 
Monday, October 11, 2021
Forward-looking statement, Arrest & Trial, Patient, Inflammation, Cirrhosis, Publication, Hebrew University of Jerusalem, TEL, Eleazar Sukenik, Non-alcoholic fatty liver disease, Liver, COVID-19, SCD, Physician, Manuscript, Drug development, Safety, PK, Population, Annual report, SEC, Kinetics, Terminology, ARMOR, FDA, Steatosis, Perception, Hepatocyte, EMA, Liver cancer, SCD1, AMPK, Hepatic stellate cell, Fatty liver disease, Clinical trial, Cardiovascular disease, Obesity, Risk, NASH, Mall of America, Pharmaceutical industry, Dietary supplement

TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).

Key Points: 
  • TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today that the one-year results of the global Phase 2b randomized placebo-controlled ARREST Trial of Aramchol in patients with NASH have been published in Nature Medicine ( https://www.nature.com/articles/s41591-021-01495-3 ).
  • The ARREST Phase 2b study randomized 247 patients with NASH confirmed by liver biopsy.
  • Data from the ARREST Phase 2b study published in this paper demonstrate how the mechanism of action of Aramchol translates into clinical performance.
  • Our lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study.